EcoDrugPlus

Aldo-Keto Reductase Family 1 Member B

Ensembl ID : ENSMICG00000001921
Gene Symbol: AKR1B1
4 Cross references
429 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Alpha Glucosidase

Ensembl ID : ENSMICG00000004729
Gene Symbol: GAA
4 Cross references
234 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Alpha-Amylase 2b

Ensembl ID : ENSMICG00000035797
Gene Symbol: LOC105864005
3 Cross references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Alpha-Amylase 2b-Like

Ensembl ID : ENSMICG00000000881
Gene Symbol: LOC105863954
3 Cross references
212 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Amine Oxidase Copper Containing 1

Ensembl ID : ENSMICG00000030675
Gene Symbol: AOC1
4 Cross references
230 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Amine Oxidase Copper Containing 3

Ensembl ID : ENSMICG00000027130
Gene Symbol: AOC3
3 Cross references
318 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Amyloid P Component, Serum

Ensembl ID : ENSMICG00000046846
Gene Symbol: APCS
4 Cross references
440 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Amyloid Beta Precursor Protein

Ensembl ID : ENSMICG00000001468
Gene Symbol: APP
4 Cross references
276 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Androgen Receptor

Ensembl ID : ENSMICG00000014721
Gene Symbol: AR
4 Cross references
277 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Angiotensin I Converting Enzyme

Ensembl ID : ENSMICG00000003785
Gene Symbol: ACE
4 Cross references
93 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSMICG00000049373
Gene Symbol: AGTR1
2 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSMICG00000044784
Gene Symbol: AGTR2
4 Cross references
191 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).